Treatment Guidelines: Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer
Dana-Farber Brigham Cancer Center Breast Oncology Center (BOC) meetings held on October 15 and November 5, 2021, was to discuss recommendations for the use of abemaciclib in patients with early-stage, high-risk, HR+ breast cancer.
